

Alzheimer's Disease Therapeutics Market - 2025-2033

<https://marketpublishers.com/r/A1BF09ACE40CEN.html>

Date: March 2026

Pages: 223

Price: US\$ 2,999.00 (Single User License)

ID: A1BF09ACE40CEN

Abstracts

The Alzheimer's Disease Therapeutics Market was valued at US\$ 5.38 billion in 2025 and is anticipated to reach US\$ 17.98 billion by 2033, at a CAGR of 0.1432 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Alzheimer's Disease Therapeutics Market.

This report delivers a comprehensive overview of the Alzheimer's Disease Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Alzheimer's Disease Therapeutics Market. The Alzheimer's Disease Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

Alzheimer's Disease Therapeutics Market Scope:

Key Players

Eli Lilly and Company

Major Highlights

This report delivers a comprehensive overview of the Alzheimer's Disease Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Alzheimer's Disease Therapeutics Market. The Alzheimer's Disease Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS

- 3.1. Key Trends and Future Projections

4. SNIPPET BY STAGE

5. SNIPPET BY DRUG CLASS

- 5.1. Snippet by Region

6. DYNAMICS

6.1. Impacting Factors

6.1.1. Drivers

- 6.1.1.1. Rising Prevalence of Alzheimer's Disease
- 6.1.1.2. Advancements in Treatment Options
- 6.1.1.3. XX

6.1.2. Restraints

- 6.1.2.1. Regulatory and Approval Challenges
- 6.1.2.2. High Treatment Costs
- 6.1.2.3. XX

6.1.3. Opportunity

- 6.1.3.1. Growing Investment in R&D and Precision Medicine
- 6.1.3.2. XX

6.1.4. Impact Analysis

7. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 7.1. Market Leaders and Pioneers

- 7.1.1. Emerging Pioneers and Prominent Players
- 7.1.2. Established Leaders with Largest Marketing Brand
- 7.1.3. Market Leaders with Established Products
- 7.2. Latest Developments and Breakthroughs
- 7.3. Regulatory and Reimbursement Landscape
 - 7.3.1. North America
 - 7.3.2. Europe
 - 7.3.3. Asia Pacific
 - 7.3.4. Latin America
 - 7.3.5. Middle East & Africa
- 7.4. Porter's Five Forces Analysis
- 7.5. Supply Chain Analysis
- 7.6. Patent Analysis
- 7.7. SWOT Analysis
- 7.8. Pipeline Analysis
- 7.9. Epidemiology Analysis
- 7.10. Unmet Needs and Gaps
- 7.11. Recommended Strategies for Market Entry and Expansion
- 7.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 7.13. Pricing Analysis and Price Dynamics
- 7.14. Key Opinion Leaders

8. ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY STAGE

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
 - 8.1.2. Market Attractiveness Index, By Stage
- 8.2. Early-stage Alzheimer's (Mild)*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Middle-stage Alzheimer's (Moderate)
- 8.4. Late-stage Alzheimer's (Severe)

9. ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY DRUG CLASS

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 9.1.2. Market Attractiveness Index, By Drug Class
- 9.2. Cholinesterase Inhibitors*

- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.2.3. Donepezil
- 9.2.4. Galantamine
- 9.2.5. Rivastigmine
- 9.3. NMDA Receptor Antagonists
 - 9.3.1. Memantine
 - 9.3.2. Others
- 9.4. Combination Drugs
 - 9.4.1. Namzaric
- 9.5. Immunotherapy
 - 9.5.1. Lecanemab
 - 9.5.2. Donanemab
 - 9.5.3. Aducanumab
- 9.6. Others

10. ALZHEIMER'S DISEASE THERAPEUTICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

11. INTRODUCTION

- 11.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 11.1.1. Market Attractiveness Index, By Region
- 11.2. North America
 - 11.2.1. Introduction
 - 11.2.2. Key Region-Specific Dynamics
 - 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
 - 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.2.5.1. U.S.
 - 11.2.5.2. Canada
 - 11.2.5.3. Mexico
- 11.3. Europe
 - 11.3.1. Introduction
 - 11.3.2. Key Region-Specific Dynamics
 - 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
 - 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.3.5.1. Germany

- 11.3.5.2. UK
- 11.3.5.3. France
- 11.3.5.4. Spain
- 11.3.5.5. Italy
- 11.3.5.6. Rest of Europe
- 11.4. Asia-Pacific
 - 11.4.1. Introduction
 - 11.4.2. Key Region-Specific Dynamics
 - 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
 - 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.4.5.1. China
 - 11.4.5.2. India
 - 11.4.5.3. Japan
 - 11.4.5.4. South Korea
 - 11.4.5.5. Rest of Asia-Pacific
- 11.5. South America
 - 11.5.1. Introduction
 - 11.5.2. Key Region-Specific Dynamics
 - 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
 - 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 11.5.4.1. Brazil
 - 11.5.4.2. Argentina
 - 11.5.4.3. Rest of South America
- 11.6. Middle East and Africa
 - 11.6.1. Introduction
 - 11.6.2. Key Region-Specific Dynamics
 - 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
 - 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

12. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

13. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS

- 13.1. Market Share Analysis and Positioning Matrix
- 13.2. Strategic Partnerships, Mergers & Acquisitions
- 13.3. Key Developments in Product Portfolios and Innovations
- 13.4. Company Benchmarking

14. COMPANY PROFILES

14.1. Eli Lilly and Company

14.1.1. Company Overview

14.1.2. Product Portfolio

14.1.2.1. Product Description

14.1.2.2. Product Key Performance Indicators (KPIs)

14.1.2.3. Historic and Forecasted Product Sales

14.1.2.4. Product Sales Volume

15. FINANCIAL OVERVIEW

15.1. Company Revenue

15.1.1. Geographical Revenue Shares

15.1.1.1. Revenue Forecasts

15.1.2. Key Developments

15.1.2.1. Mergers & Acquisitions

15.1.2.2. Key Product Development Activities

15.1.2.3. Regulatory Approvals, etc.

15.1.3. SWOT Analysis

15.2. Pfizer Inc.

15.3. Merck & Co., Inc.

15.4. Eisai Co., Ltd.

15.5. Merz Therapeutics

15.6. Otsuka Pharmaceutical Co., Ltd.

15.7. Alpha Cognition

15.8. Johnson & Johnson Services, Inc.

15.9. Assumption and Research Methodology

15.9.1. Data Collection Methods

15.9.2. Data Triangulation

15.9.3. Forecasting Techniques

15.9.4. Data Verification and Validation

16. APPENDIX

16.1. About Us and Services

16.2. Contact Us

I would like to order

Product name: Alzheimer's Disease Therapeutics Market - 2025-2033

Product link: <https://marketpublishers.com/r/A1BF09ACE40CEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A1BF09ACE40CEN.html>